Health Trials

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

ConditionsUltra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High RiskPrimary RefractoryEarly ProgressionPlasma Cell LeukemiaNon Paraosseous Extramedullary InfiltrationR2-ISS-IV /MPSS-IV
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorInstitute of Hematology & Blood Diseases Hospital, China

About this trial

To evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (ASCT) combined with BCMA-CART in the treatment of UHR-MM.

Eligibility criteria

Qualifiers

The subjects voluntarily participated in the study and signed the informed consent form (ICF) by themselves or their legal guardians;

Disqualifiers

Have a history of allergy to any component in cell products;

History of autologous / allogeneic hematopoietic stem cell transplantation;

Stroke or seizure within 6 months before signing ICF;

Have autoimmune disease, immune deficiency or other diseases requiring immunosuppressant treatment;

Trial design

Treatments tested in this trial

  • BCMA CART

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators

Institute of Hematology & Blood Diseases Hospital, China

Lead sponsor

Hebei Taihe Chunyu Biotechnology Co., Ltd

Collaborator

Source ClinicalTrials.gov